Superior Planning, LLC’s Rapport Therapeutics RAPP Stock Holding History

Superior Planning, LLC’s Portfolio RAPP Stock Details RAPP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.59K	Buy	+77	New	+$3.32K	﹤0.01%	1472

Other funds holding RAPP

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Superior Planning, LLC's RAPP Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Rapport Therapeutics (RAPP) in Q3 2026: 77 shares worth $2.59K. The stake represents ﹤0.01% of the portfolio and ranks #1472 among its holdings.

89 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.

Superior Planning, LLC held 77 shares of Rapport Therapeutics worth $2.59K as of Q3 2026.
Rapport Therapeutics was a new Superior Planning, LLC position in Q3 2026.
Rapport Therapeutics made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1472 holding.
89 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.